PD-L1 Protein, Human, Recombinant (His Tag)


PD-L1 Protein, Human, Recombinant (His Tag): Product Information

> 98 % as determined by SDS-PAGE
< 1.0 EU per μg of the protein as determined by the LAL method
Measured by its binding ability in a functional ELISA . Immobilized human B7-H1 at 20 μg/ml (100 μl/well) can bind human PD1 with a linear ranger of 0.032-0.8 μg/ml .
Protein Construction
A DNA sequence encoding the N-terminal segment (Met 1-Thr 239) of the extracellular domain of human B7-H1 (NP_054862.1) was expressed with a C-terminal polyhistidine tag.
Expressed Host
HEK293 Cells
Predicted N Terminal
Phe 19
Molecule Mass
The recombinant mature human B7-H1 comprises 232 amino acids and predicts a molecular mass of 26.8 kDa. As a result of glycosylation, the rh B7-H1 migrates as an approximately 35-38 kDa protein in SDS-PAGE under reducing conditions.
Lyophilized from sterile PBS, pH 7.4
Please contact us for any concerns or special requirements.
Please refer to the specific buffer information in the hard copy of CoA.
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Stability & Storage
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃
Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

PD-L1 Protein, Human, Recombinant (His Tag): Images

Measured by its binding ability in a functional ELISA . Immobilized human B7-H1 at 20 μg/ml (100 μl/well) can bind human PD1 with a linear ranger of 0.032-0.8 μg/ml

PD-L1 Protein, Human, Recombinant (His Tag): Alternative Names

B7-H Protein, Human; B7-H1 Protein, Human; B7H1 Protein, Human; PD-L1 Protein, Human; PDCD1L1 Protein, Human; PDCD1LG1 Protein, Human; PDL1 Protein, Human

PD-L1 Background Information

Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. PD-L1/B7-H1 is a member of the growing B7 family of immune molecules and this protein contains one V-like and one C-like Ig domain within the extracellular domain, and together with PD-L2, are two ligands for PD1 which belongs to the CD28/CTLA4 family expressed on activated lymphoid cells. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.
Full Name
CD274 molecule
  • Iwai Y, et al. (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 99(19): 12293-7.
  • Ghebeh H, et al. (2006) The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia. 8(3): 190-8.
  • Salih HR, et al. (2006) The role of leukemia-derived B7-H1 (PD-L1) in tumor-T-cell interactions in humans. Exp Hematol. 34(7): 888-94.
  • Wilcox RA, et al. (2009) B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood. 114(10): 2149-58.
  • Ruggiero A, et al. (2009) Crystal structure of PD-L1, a ribosome inactivating protein from Phytolacca dioica L. leaves with the property to induce DNA cleavage. Biopolymers. 91(12): 1135-42.
  • Design, isolation and evaluation of the binding efficiency of a DNA aptamer against interleukin 2 receptor alpha, in vitro
    Shahdordizadeh, M;Taghdisi, SM;Sankian, M;Ramezani, M;Abnous, K;
    Int. Immunopharmacol.
  • Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers
    Broos, K;Keyaerts, M;Lecocq, Q;Renmans, D;Nguyen, T;Escors, D;Liston, A;Raes, G;Breckpot, K;Devoogdt, N;
  • Novel Humanized Monoclonal Antibodies to PD-L1
    Simonetti, M;Alton, K;Shimkets, R;
    Abeome Intelligent Antibody Discovery
  • Selection of DNA aptamers against Mycobacterium tuberculosis Ag85A, and its application in a graphene oxide-based fluorometric assay
    Ansari, N;Ghazvini, K;Ramezani, M;
    Microchimica Acta
  • A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression
    Mahoney, KM;Shukla, SA;Patsoukis, N;Chaudhri, A;Browne, EP;Arazi, A;Eisenhaure, TM;Pendergraft, WF;Hua, P;Pham, HC;Bu, X;Zhu, B;Hacohen, N;Fritsch, EF;Boussiotis, VA;Wu, CJ;Freeman, GJ;
    Cancer Immunol. Immunother.
    SDS-PAGE and WB (control)
Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait